Inherited Retinal Disease
Beacon Therapeutics (USA) Inc. is focused on inherited retinal disorders, with research activity centered on X-linked retinitis pigmentosa linked to RPGR mutations. The sponsor’s clinical work is directed toward conditions that affect the structure and function of the retina.
- X-linked retinitis pigmentosa
- RPGR-associated retinal disease
- Retinal degeneration
The therapeutic emphasis is on preserving visual function in a progressive retinal dystrophy population.
Ophthalmic Gene Therapy
The sponsor’s research includes ocular gene therapy approaches designed for direct treatment of the eye, with particular attention to restoring or supporting retinal activity in genetic vision loss.
- Gene-based ophthalmology
- Retinal gene delivery
- Genetic vision disorders
Its therapeutic interest lies in interventions intended for inherited conditions where targeted retinal treatment is central.
Subretinal Administration
Beacon Therapeutics is active in research involving subretinal administration, a route used to place therapy directly within the retinal environment. This area reflects a focus on localized treatment for diseases affecting the photoreceptors and surrounding retinal tissue.
- Subretinal delivery
- Retinal targeting
- Photoreceptor support
The sponsor’s clinical interest is concentrated on eye-specific intervention strategies for inherited retinal impairment.
Visual Function Assessment
Clinical research activity also includes evaluation of visual function in people with retinal disease, with attention to measures that capture macular integrity and functional vision performance.
- Macular integrity
- Microperimetry
- Functional vision outcomes
This area supports the sponsor’s work in understanding how retinal therapies relate to changes in central visual performance.
